ArticleFrontiers in oncology2026
Biologically effective doses for α/β = 10 (BED
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal biologically effective dose (BED Methods: 46 patients with pancreatic cancer treated with SBRT (May 2021-December 2023) were retrospectively analyzed. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan-Meier method with log-rank testing. Multivariable Cox regression was performed adjusting for disease stage, chemotherapy, tumor size, dose group, and fiducial marker status, with exploratory interaction and subgroup analyses. Results: Among the 46 patients (10 Stage I/II, 17 locally advanced, 19 metastatic), median OS was 13.0 months (95% CI: 9.9-16.1), with 1-year OS of 51.2% (<80 Gy) vs. 53.3% (≥80 Gy) (log-rank p=0.442). Multivariable analysis showed no significant dose effect (HR 1.472, p=0.342). Independent prognostic factors were disease stage (HR 0.274, p=0.006), tumor size (HR 0.399, p=0.026), chemotherapy (HR 0.410, p=0.029), and absence of fiducial markers (HR 4.224, p=0.006). No significant dose × stage (p=0.373) or dose × chemotherapy (p=0.104) interactions were observed. In 27 patients with evaluable imaging, LC was 92.6% and median PFS was 8.0 vs. 10.0 months (log-rank p=0.605). Conclusion: In this single-center retrospective analysis, BED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.